Fixed combinations in the pragmatic management of hypertension: focus on aliskiren and hydrochlorothiazide as a single pill

References

• ChobanianAVBakrisGLBlackHRSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension2003421206125214656957
   PubMed Web of Science ®Google Scholar
• CifkovaRErdineSFagardRPractice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelinesJ Hypertens2003211779178614508180
   PubMedGoogle Scholar
• BakrisGLWilliamsMDworkinLPreserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working GroupAm J Kidney Dis20003664666110977801
   PubMed Web of Science ®Google Scholar
• CushmanWCFordCECutlerJASuccess and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)J Clin Hypertens (Greenwich)2002439340412461301
   PubMedGoogle Scholar
• HanssonLZanchettiACarruthersSGEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study GroupLancet1998351175517629635947
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med20083592417242819052124
   PubMed Web of Science ®Google Scholar
• BurnierMGasserUEEfficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practiceExpert Opin Pharmacother200782215222317927478
   PubMed Web of Science ®Google Scholar
• SicaDARationale for fixed-dose combinations in the treatment of hypertension: the cycle repeatsDrugs20026244346211827559
   PubMed Web of Science ®Google Scholar
• KocharMGuthrieRTriscariJKassler-TaubKReevesRAMatrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertensionAm J Hypertens19991279780510480473
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJMorrisJKJordanREValue of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ2003326142712829555
   PubMed Web of Science ®Google Scholar
• BurnierMAngiotensin II type 1 receptor blockersCirculation200110390491211171802
   PubMed Web of Science ®Google Scholar
• FerrariPHessLPechere-BertschiAMuggliFBurnierMReasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention studyJ Hypertens2004221221122915167458
   PubMed Web of Science ®Google Scholar
• WaldNJLawMRA strategy to reduce cardiovascular disease by more than 80%BMJ2003326141912829553
   PubMed Web of Science ®Google Scholar
• VrijensBVinczeGKristantoPUrquhartJBurnierMAdherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing historiesBMJ20083361114111718480115
   PubMed Web of Science ®Google Scholar
• GerthWCCompliance and persistence with newer antihypertensive agentsCurr Hypertens Rep2002442443312419170
   PubMed Web of Science ®Google Scholar
• ChapmanRHBennerJSPetrillaAAPredictors of adherence with antihypertensive and lipid-lowering therapyArch Intern Med20051651147115215911728
   PubMed Web of Science ®Google Scholar
• van WijkBLKlungelOHHeerdinkERdeBARate and determinants of 10-year persistence with antihypertensive drugsJ Hypertens2005232101210716208154
   PubMed Web of Science ®Google Scholar
• BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: a meta-analysisAm J Med200712071371917679131
   PubMed Web of Science ®Google Scholar
• RuilopeLMBurnierMMuszbekNPublic health value of fixed-dose combinations in hypertensionBlood Press Suppl2008151418705530
   PubMedGoogle Scholar
• NussbergerJWuerznerGJensenCBrunnerHRAngiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalaprilHypertension200239E1E811799102
   PubMed Web of Science ®Google Scholar
• WoodJMSchnellCRCuminFMenardJWebbRLAliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive ratsJ Hypertens20052341742615662231
   PubMed Web of Science ®Google Scholar
• NussbergerJAubertJFBouzoureneKPellegrinMHayozDMazzolaiLRenin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipineHypertension2008511306131118391092
   PubMed Web of Science ®Google Scholar
• PilzBShagdarsurenEWellnerMAliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic ratsHypertension20054656957616103264
   PubMed Web of Science ®Google Scholar
• GradmanAHSchmiederRELinsRLNussbergerJChiangYBedigianMPAliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patientsCirculation20051111012101815723979
   PubMed Web of Science ®Google Scholar
• StantonAJensenCNussbergerJO’BrienEBlood pressure lowering in essential hypertension with an oral renin inhibitor, aliskirenHypertension2003421137114314597641
   PubMed Web of Science ®Google Scholar
• DietzRDechendRYuCMEffects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1J Renin Angiotensin Aldosterone Syst2008916317518957387
   PubMed Web of Science ®Google Scholar
• OparilSYarowsSAPatelSFangHZhangJSatlinAEfficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trialLancet200737022122917658393
   PubMed Web of Science ®Google Scholar
• SchmiederREPhilippTGuerediagaJLong-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazideCirculation200911941742519139391
   PubMed Web of Science ®Google Scholar
• VillamilAChrysantSGCalhounDRenin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazideJ Hypertens20072521722617143194
   PubMed Web of Science ®Google Scholar
• AndersenKWeinbergerMHEganBComparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trialJ Hypertens20082658959918300872
   PubMed Web of Science ®Google Scholar
• JordanJEngeliSBoyeSWLeBSKeefeDLDirect Renin inhibition with aliskiren in obese patients with arterial hypertensionHypertension2007491047105517353513
   PubMed Web of Science ®Google Scholar
• NickenigGSimanenkovVLemboGEfficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-respondersBlood Press200817Suppl 2314020973654
   PubMed Web of Science ®Google Scholar
• DrummondWMungerMARafiqueEMMaboudianMKhanMKeefeDLAntihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapyJ Clin Hypertens (Greenwich)2007974275017917501
   PubMedGoogle Scholar
• FeldmanRDZouGYVandervoortMKWongCJNelsonSAFeaganBGA simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trialHypertension20095364665319237683
   PubMed Web of Science ®Google Scholar
• VerdecchiaPAngeliFMazzottaGGentileGReboldiGThe renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reductionVasc Health Risk Manag2008497198119183745
   PubMedGoogle Scholar